| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| 250g |
|
||
| Other Sizes |
| Targets |
1-Benzyl-4-piperidone itself does not have a specific biological target; it is a synthetic intermediate. However, drug molecules synthesized from it have well-defined targets. For instance, donepezil (derived from 1-benzyl-4-piperidone) is a reversible acetylcholinesterase (AChE) inhibitor used to increase acetylcholine levels in the brains of Alzheimer's patients. Other derivatives target sigma-1 receptors, NMDA receptors, and various GPCRs. Thus, the compound enables access to molecules with diverse target profiles.
|
|---|---|
| ln Vitro |
An analytical reference standard that is structurally categorized as a piperidine is N-benzyl-4-piperidone. It is an ingredient in the manufacture of substances similar to fentanyl. This compound's physiological and toxicological characteristics are unknown. Applications in forensics and research are the target markets for this device.
1-Benzyl-4-piperidone has no direct in vitro biological activity of its own. It is not cytotoxic or antiproliferative at typical reagent concentrations. However, derivatives synthesized from it exhibit potent in vitro activities: For example, donepezil shows IC50 of 9-12 nM for human AChE, while spirocyclic derivatives from 1-benzyl-4-piperidone have been reported as high-affinity sigma-1 receptor ligands (Ki <10 nM). The parent intermediate is not tested in these assays. |
| ln Vivo |
No in vivo activity data are available for 1-Benzyl-4-piperidone itself, as it is not administered to animals for efficacy testing. In contrast, its derivative donepezil is extensively studied in animal models of Alzheimer's disease. Typical in vivo studies: APPswe/PS1dE9 transgenic mice or scopolamine-induced amnesia rats are treated with donepezil (0.5-5 mg/kg i.p. or p.o.). Cognitive improvements are measured by Morris water maze (escape latency decreased by 30-50%) and Y-maze (spontaneous alternation increased by 20-30%). 1-Benzyl-4-piperidone is not tested.
|
| Enzyme Assay |
The compound is not used in enzyme binding assays. Instead, standard organic chemistry protocols describe its use as a building block. A typical protocol for nucleophilic addition to the ketone: Dissolve 1-Benzyl-4-piperidone (0.01 mol) in anhydrous THF. Add the organolithium or Grignard reagent (0.012 mol) dropwise at -78degC under nitrogen. Stir for 2 hours, then allow to warm to room temperature. Quench with saturated NH4Cl, extract with ethyl acetate, dry over Na2SO4, and concentrate. Purify by column chromatography. The resulting tertiary alcohol can be further transformed.
|
| Cell Assay |
1-Benzyl-4-piperidone is not directly tested in cell-based assays. However, in cell-based assays for Alzheimer's research, derivatives such as donepezil are tested in neuroblastoma cell lines (SH-SY5Y, SK-N-SH). A typical protocol: Cells are seeded in 96-well plates (10,000 cells/well) and treated with test compound (0.01-10 microM) for 24-48 hours. AChE activity is measured in cell lysates using Ellman's method (acetylthiocholine as substrate, DTNB as chromogen, absorbance at 412 nm). Cytotoxicity is assessed by LDH release or MTT assay. 1-Benzyl-4-piperidone is not tested.
|
| Animal Protocol |
1-Benzyl-4-piperidone is not tested in animal models. However, for the development of multi-target-directed ligands (MTDLs) for Alzheimer's disease, the compound is used as a starting material to generate libraries of donepezil-propargylamine-8-hydroxyquinoline hybrids. Those hybrids are then tested in mice: 6-week-old C57BL/6 mice are treated orally with the hybrid (10-50 mg/kg) for 7 days, then memory is assessed using novel object recognition. After sacrifice, brains are harvested, and AChE activity, oxidative stress markers (MDA, SOD), and amyloid plaque burden are measured. 1-Benzyl-4-piperidone is not administered.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for 1-Benzyl-4-piperidone. However, for the derivative donepezil, PK data in humans: oral bioavailability ~100%, peak plasma concentration reached in 3-4 hours, plasma protein binding ~96%, half-life ~70 hours, metabolized primarily by CYP3A4 and CYP2D6. The compound's use as an intermediate is not associated with any ADME data. The free base may have moderate oral absorption if administered, but this is not studied.
|
| Toxicity/Toxicokinetics |
According to safety data sheets (SDS), 1-Benzyl-4-piperidone may cause skin and eye irritation. It is harmful if swallowed (oral LD50 500-2000 mg/kg predicted). Inhalation of dust may cause respiratory irritation. Not classified as a carcinogen. However, it is known to be used in the synthesis of fentanyl analogs (Schedule II controlled substances), and therefore the compound itself has regulatory restrictions in many jurisdictions. Use only in a well-ventilated fume hood with appropriate PPE.
|
| Additional Infomation |
Structure in the first source
1-Benzyl-4-piperidone is not a drug itself but is a crucial pharmaceutical intermediate for the synthesis of donepezil (Aricept), an FDA-approved drug (1996) for the treatment of Alzheimer's disease, and for galantamine (Razadyne), another Alzheimer's medication. The compound is also used to synthesize fentanyl (Schedule II controlled substance), leading to its classification as a DEA List I chemical in the United States. As such, access is restricted in many countries. No clinical trials are conducted with the intermediate. It remains a research chemical for academic and industrial medicinal chemistry. |
| Molecular Formula |
C12H15NO
|
|---|---|
| Molecular Weight |
189.25
|
| Exact Mass |
189.115
|
| CAS # |
3612-20-2
|
| PubChem CID |
19220
|
| Appearance |
Light yellow to brown liquid（Density：1.021 g/cm3）
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
278.5±0.0 °C at 760 mmHg
|
| Flash Point |
130.8±11.9 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.562
|
| LogP |
1.19
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
187
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])([H])C([H])([H])N(C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])C([H])([H])C1([H])[H]
|
| InChi Key |
SJZKULRDWHPHGG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H15NO/c14-12-6-8-13(9-7-12)10-11-4-2-1-3-5-11/h1-5H,6-10H2
|
| Chemical Name |
1-benzylpiperidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2840 mL | 26.4201 mL | 52.8402 mL | |
| 5 mM | 1.0568 mL | 5.2840 mL | 10.5680 mL | |
| 10 mM | 0.5284 mL | 2.6420 mL | 5.2840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
